Global Skin Cancer Diagnostics Market Forecast 2023-2032

The global skin cancer diagnostics market is projected to grow with a CAGR of 7.13% during the forecast period 2023-2032. The market's growth is mainly fueled by the increasing prevalence of skin cancer, the surging awareness about skin cancer diagnosis & treatment, as well as technological advancements in skin cancer diagnostic products.

MARKET INSIGHTS

Skin cancer diagnostics entails the segment of the healthcare industry that covers various technologies, products, and services associated with the diagnosis, assessment, and detection of skin cancer. Skin cancer diagnostics methods generally include an amalgamation of visual inspection, dermoscopy, clinical examination, and tissue samples' histopathological analysis.

Advanced technologies, including artificial intelligence (AI), are being widely utilized for the development of innovative skin cancer detection systems, capable of identifying the condition more efficiently and accurately compared to conventional methods. For instance, DermTech developed an AI-powered skin cancer detection system termed Athena. The system has demonstrated high accuracy in terms of identifying skin cancer. As a result, such cutting-edge technological advancements in skin cancer diagnostic products are projected to play an essential role in fueling the global skin cancer diagnostics market growth during the forecast period.

REGIONAL INSIGHTS

The global skin cancer diagnostics market growth analysis covers the study of North America, Europe, Asia-Pacific, and Rest of World. The market in North America is set to capture the highest revenue share by 2023. The regional market's growth is propelled by key factors, such as significant investments in the research & development of skin cancer diagnostics products by major players as well as the increasing prevalence of skin cancer.

COMPETITIVE INSIGHTS

The industrial rivalry in the global skin cancer diagnostics market is expected to be high during the forecast period. Moreover, players with a larger product portfolio and significant R&D investments create strong competition in the global market. Some of the top companies operating in the market include DermTech Inc, Michelson Diagnostics Ltd, NeraCare GmbH, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 51891

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
- 2.5.1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS
- 2.5.2. EXPANDING DEMAND FOR SKIN CANCER DIAGNOSTICS IN AUSTRALIA

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. INCREASING PREVALENCE OF SKIN CANCER
- 3.1.2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
- 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
- 3.2.2. STRINGENT REGULATORY FRAMEWORK
- 3.2.3. LACK OF SKILLED MEDICAL PROFESSIONALS

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
- 4.6.1. RESEARCH AND DEVELOPMENT
- 4.6.2. MANUFACTURING
- 4.6.3. MARKETING AND SALES
- 4.6.4. DISTRIBUTION AND LOGISTICS
- 4.6.5. TRAINING AND SUPPORT

5. MARKET BY TYPE

5.1. MELANOMA
5.2. NON-MELANOMA

6. MARKET BY GENDER

6.1. MALE
6.2. FEMALE

7. MARKET BY SCREENING TYPE

7.1. SKIN BIOPSY
7.2. DERMATOSCOPY
7.3. LYMPH NODE
7.4. BIOPSY IMAGING TESTS
7.5. BLOOD TESTS

8. GEOGRAPHICAL ANALYSIS

8.1. NORTH AMERICA
- 8.1.1. MARKET SIZE & ESTIMATES
- 8.1.2. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET DRIVERS
- 8.1.3. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
- 8.1.4. KEY PLAYERS IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
- 8.1.5. COUNTRY ANALYSIS
  - 8.1.5.1. UNITED STATES
  - 8.1.5.1.1. UNITED STATES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.1.5.2. CANADA
  - 8.1.5.2.1. CANADA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
- 8.2.1. MARKET SIZE & ESTIMATES
- 8.2.2. EUROPE SKIN CANCER DIAGNOSTICS MARKET DRIVERS
- 8.2.3. EUROPE SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
- 8.2.4. KEY PLAYERS IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
- 8.2.5. COUNTRY ANALYSIS
  - 8.2.5.1. UNITED KINGDOM
  - 8.2.5.1.1. UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.2. GERMANY
  - 8.2.5.2.1. GERMANY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.3. FRANCE
  - 8.2.5.3.1. FRANCE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.4. ITALY
  - 8.2.5.4.1. ITALY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.5. SPAIN
  - 8.2.5.5.1. SPAIN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.6. NORDIC COUNTRIES
  - 8.2.5.6.1. NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.7. BELGIUM
  - 8.2.5.7.1. BELGIUM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.8. POLAND
  - 8.2.5.8.1. POLAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.2.5.9. REST OF EUROPE
  - 8.2.5.9.1. REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
- 8.3.1. MARKET SIZE & ESTIMATES
- 8.3.2. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET DRIVERS
- 8.3.3. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
- 8.3.4. KEY PLAYERS IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
- 8.3.5. COUNTRY ANALYSIS
  - 8.3.5.1. CHINA
  - 8.3.5.1.1. CHINA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.2. JAPAN
  - 8.3.5.2.1. JAPAN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.3. INDIA
  - 8.3.5.3.1. INDIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.4. SOUTH KOREA
  - 8.3.5.4.1. SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.5. INDONESIA
  - 8.3.5.5.1. INDONESIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.6. THAILAND
  - 8.3.5.6.1. THAILAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.7. VIETNAM
  - 8.3.5.7.1. VIETNAM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.8. AUSTRALIA & NEW ZEALAND
  - 8.3.5.8.1. AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.3.5.9. REST OF ASIA-PACIFIC
  - 8.3.5.9.1. REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
- 8.4.1. MARKET SIZE & ESTIMATES
- 8.4.2. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET DRIVERS
- 8.4.3. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
- 8.4.4. KEY PLAYERS IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET
- 8.4.5. REGIONAL ANALYSIS
  - 8.4.5.1. LATIN AMERICA
  - 8.4.5.1.1. LATIN AMERICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
  - 8.4.5.2. MIDDLE EAST & AFRICA
  - 8.4.5.2.1. MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.2. PARTNERSHIPS & AGREEMENTS
9.2. COMPANY PROFILES
- 9.2.1. AMLO BIOSCIENCES LIMITED
- 9.2.2. BIOMERIEUX SA
- 9.2.3. CASTLE BIOSCIENCES INC
- 9.2.4. DERMLITE LLC
- 9.2.5. DERMTECH INC
- 9.2.6. F. HOFFMANN-LA ROCHE LTD
- 9.2.7. MICHELSON DIAGNOSTICS LTD
- 9.2.8. NERACARE GMBH
- 9.2.9. SKYLINEDX BV
- 9.2.10. VERISKIN INC